Faria Andre, Macedo Arthur, Castro Carolina, Valle Elke, Lacerda Raquel, Ayas Najib, Laher Ismail
Universidade Federal de Minas Gerais, Faculdade de Medicina - Belo Horizonte - MG - Brazil.
University of British Columbia, Divisions of Critical Care and Respiratory Medicine - Vancouver - BC - Canada.
Sleep Sci. 2022 Apr-Jun;15(2):250-258. doi: 10.5935/1984-0063.20220047.
Cardiovascular diseases (CVDs) are the leading causes of mortality worldwide, accounting for nearly 18 million deaths per year. Among other considerations, treating CVDs requires better understanding their risk factors. Sleep-disordered breathing, especially obstructive sleep apnea (OSA), is a likely contributor to several CVDs. We review key epidemiological data that addresses the link between OSA and cardiovascular outcomes such as hypertension, atrial fibrillation (AF), stroke, atherosclerosis, and heart failure (HF), and proposed pathophysiological mechanisms underlying this association. There are several biological pathways linking OSA and an increased propensity to cardiovascular diseases, and we discuss the evidence on the benefits of treatments of OSA on the prevalence of cardiovascular complications.
心血管疾病（CVDs）是全球死亡的主要原因，每年导致近1800万人死亡。在其他需要考虑的因素中，治疗心血管疾病需要更好地了解其危险因素。睡眠呼吸紊乱，尤其是阻塞性睡眠呼吸暂停（OSA），可能是多种心血管疾病的一个促成因素。我们回顾了关键的流行病学数据，这些数据涉及阻塞性睡眠呼吸暂停与心血管结局（如高血压、心房颤动（AF）、中风、动脉粥样硬化和心力衰竭（HF））之间的联系，并提出了这种关联背后的病理生理机制。有几种生物学途径将阻塞性睡眠呼吸暂停与心血管疾病易感性增加联系起来，我们讨论了阻塞性睡眠呼吸暂停治疗对心血管并发症患病率益处的证据。
